AlloVir Inc

AlloVir Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for viral diseases. The company is particularly known for its work in creating allogeneic, off-the-shelf, virus-specific T-cell therapies designed to treat and prevent life-threatening viral infections in immunocompromised patients, such as those undergoing stem cell or organ transplants. AlloVir's lead product candidate, Viralym-M, targets five common and devastating viruses, including BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, and human herpesvirus-6. The company leverages its proprietary technology platform to develop these therapies, aiming to address significant unmet medical needs in the field of infectious diseases. With a strong management team and support from experienced investors, AlloVir is advancing its pipeline through clinical trials, seeking to provide effective solutions for patients with limited treatment options.